Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and investors to an informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Lund (20 June) and Stockholm (21 June).
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Lund or Stockholm during the Midsummer week to hear an update on the company, learn more about the ongoing rights issue, and ask your most pressing questions.
The event is free of charge, and wine and snacks will be served. As seats are limited, please respond quickly to reserve your space.
Lund, 20 June, 16:00 – 18:00 p.m. CEST:
Restaurant Inspira, Medicon Village, Scheeletorget 1.
Stockholm, 21 June, 16:00 – 18:00 p.m. CEST:
Erik Penser Bank, Apelbergsgatan 27.
Please respond to firstname.lastname@example.org to reserve your space.
Watch the interview with CEO Ellen Donnelly by #InvestTalks, June 13, 2022: https://youtu.be/CT8cL1LVF1w.